Global Genome Editing/Genome Engineering Market Size By Type (CRISPR, TALEN), By Application (Cell Line Engineering, Animal Genetic Engineering), By Region, And Segment Forecasts, 2023 to 2032

The Global Genome Editing/Genome Engineering Market was valued at USD 6.4 billion in 2023 and is projected to reach USD 20.1 billion by 2031, growing at a CAGR of 15.7% during the forecast period from 2023 to 2031. Genome editing refers to a group of technologies that allow scientists to modify an organism's DNA, and it's revolutionizing healthcare, agriculture, and biological research. Major drivers include increased funding in genomic research, rising prevalence of genetic disorders, and the expansion of CRISPR-based technologies.

Advancements in gene therapy and personalized medicine have also been significant contributors, alongside regulatory approvals and rising investments from both public and private sectors.

Drivers:

1. Growing Prevalence of Genetic Disorders:

The increasing incidence of inherited diseases such as cystic fibrosis, hemophilia, and sickle cell anemia is boosting the adoption of genome editing technologies for therapeutic purposes.

2. Advancements in CRISPR and Other Editing Tools:

Technological breakthroughs, especially in CRISPR-Cas9, TALENs, and ZFNs, are enhancing precision, efficiency, and accessibility in genome engineering applications.

3. Expanding Applications in Agriculture and Livestock:

Genome editing is increasingly used in agriculture to develop genetically modified crops that are drought-resistant, pest-resistant, and nutrient-enriched, driving market demand from agrigenomics.

Restraints:

1. Ethical and Regulatory Challenges:

Ethical concerns over human gene editing and strict regulatory scrutiny in many countries could hinder market growth and slow the pace of technology deployment.

2. High Cost of Advanced Gene Editing Technologies:

Despite advancements, the setup cost for genome editing labs and research tools remains high, particularly affecting small-scale research organizations.

Opportunity:

1. Increased Focus on Personalized Medicine:

The ongoing transition from a “one-size-fits-all” approach to personalized and precision medicine is creating a strong demand for genome editing tools in disease diagnosis and treatment.

2. Emerging Economies Investing in Genomic Research:

Countries like China and India are expanding their biotechnology sectors with government support, creating new market opportunities for global players.

3. Industrial and Synthetic Biology Applications:

Genome engineering is increasingly being used for the development of bio-based chemicals, fuels, and materials, offering high growth potential beyond healthcare.

Market by System Type Insights:

Based on system type, the CRISPR-Cas9 segment dominated the market in 2023. CRISPR technology has gained significant traction due to its ease of use, cost-effectiveness, and high precision in gene editing. This segment is expected to retain its dominance, fueled by increasing research output and successful therapeutic trials.

Other key segments include TALENs (Transcription Activator-Like Effector Nucleases) and ZFNs (Zinc Finger Nucleases), with growing interest in newer platforms such as Base Editing and Prime Editing for higher specificity and fewer off-target effects.

Market by End-use Insights:

The Pharmaceutical & Biotechnology Companies segment held the largest market share in 2023, accounting for over 45% of total revenue. These companies are actively leveraging genome editing technologies for drug development, target validation, and the production of biologics.

The Academic & Research Institutions segment is also experiencing robust growth, backed by funding from governmental bodies for genome-centric studies.

Market by Regional Insights:

North America led the global genome editing market in 2023, attributed to a strong presence of biotech firms, well-established healthcare infrastructure, and significant R&D expenditure. The U.S. remains the largest contributor due to early adoption of CRISPR technologies and favorable regulatory frameworks.

Asia-Pacific is anticipated to register the highest CAGR through 2031, driven by government-funded genomics projects, rising awareness, and the proliferation of biotech startups in countries like China, India, and South Korea.

Competitive Scenario:

Key market players in the global genome editing/genome engineering market include:

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Thermo Fisher Scientific

Sangamo Therapeutics

Precision BioSciences

GenScript

Merck KGaA

Agilent Technologies

Horizon Discovery Group

These companies are focused on expanding their product pipelines, forming academic and industry partnerships, and launching clinical trials to treat genetic diseases.

Scope of Work – Global Genome Editing/Genome Engineering Market

Report Metric Details

Market Size (2023) USD 6.4 billion

Projected Market Size (2031) USD 20.1 billion

CAGR (2023-2031) 15.7%

Market Segments By System Type (CRISPR, TALENs, ZFNs, etc.), By End-use (Pharma & Biotech, Academic Research, etc.), By Region

Growth Drivers Rise in genetic disorders, CRISPR technology adoption, funding in genomic research

Opportunities Personalized medicine, emerging markets, synthetic biology

Key Market Developments:

2023: Intellia Therapeutics initiated a Phase 3 trial using in vivo CRISPR-based therapy for hereditary angioedema, a rare genetic disease.

2024: Thermo Fisher Scientific launched an upgraded genome editing kit with reduced off-target effects and faster editing capabilities.

2025: Merck KGaA announced a strategic partnership with a Chinese biotech firm to develop genome-edited cell lines for biologics production in Asia.

FAQs:

1) What is the current market size of the Global Genome Editing/Genome Engineering Market?

The market was valued at USD 6.4 billion in 2023.

2) What is the major growth driver of the Global Genome Editing/Genome Engineering Market?

The major driver is the increasing adoption of CRISPR and related technologies for disease treatment and agricultural applications.

3) Which is the largest region during the forecast period in the Global Genome Editing/Genome Engineering Market?

North America is expected to remain the largest regional market through 2031.

4) Which segment accounted for the largest market share in the Global Genome Editing/Genome Engineering Market?

The CRISPR-Cas9 system type segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Genome Editing/Genome Engineering Market?

Key players include CRISPR Therapeutics, Editas Medicine, Thermo Fisher Scientific, Intellia Therapeutics, and Sangamo Therapeutics.